Financial Data and Key Metrics Changes - Total revenue for Q2 2024 was $146 million, reflecting a 25% year-over-year growth, with surgical revenue growth at 27% [3][22] - Adjusted EBITDA was $5.6 million, compared to a loss of $3.1 million in the prior year, marking a 650 basis point improvement [26] - Non-GAAP gross margin increased to 71.2%, up 190 basis points year-over-year [24] Business Line Data and Key Metrics Changes - Surgical revenue was $130 million, up 27% year-over-year, with significant growth in lateral and expandable implants [22] - EOS revenue reached $15.5 million, a 6% increase compared to the previous year [22] - Average surgical revenue per case grew by 10%, indicating effective procedural strategies [4][22] Market Data and Key Metrics Changes - The company experienced a 20% growth in new surgeon users, reflecting strong market demand [3][19] - Established territories saw a 23% growth, indicating successful market penetration [20] Company Strategy and Development Direction - The company is focused on creating a comprehensive spine ecosystem to enhance surgical predictability and outcomes [5][8] - Plans to achieve $1 billion in revenue by 2027, with an adjusted EBITDA target of $180 million [21] - The launch of EOS Insight is a key strategic initiative aimed at improving surgical planning and execution [4][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven by 2025, supported by anticipated revenue growth [28][80] - The company is addressing supply constraints and expects to resolve these issues, which will positively impact future revenue [72] - The competitive landscape remains favorable, with ongoing recruitment efforts to enhance the sales force [19][38] Other Important Information - The company ended Q2 with $100 million in cash and $531 million in debt, with a projected cash burn of $125 million to $135 million for 2024 [27][28] - The company is investing heavily in inventory and instrument sets to support growth initiatives [27] Q&A Session Summary Question: Confirmation of cash burn expectations for 2024 - The company confirmed an expected cash burn of $125 million to $135 million for 2024 [34] Question: Will cash need to be raised against the portfolio? - Management indicated confidence in achieving cash flow breakeven in 2025 without needing to raise additional cash [36] Question: Expected hiring trends for 2024 - The company is actively recruiting and expects robust hiring trends, particularly in geographic areas with high demand [38] Question: Update on territory upgrades - The company is methodically upgrading territories to enhance sales coverage and align with surgeon demand [42] Question: Impact of supply constraints on revenue - Management acknowledged that supply constraints had a negative impact on revenue but expected resolution in the near term [72] Question: Update on Japan market entry - The company is optimistic about entering the Japanese market, with plans to conduct surgeries there by Q4 2024 [76]

Revenue and Growth - Revenue from products and services increased by $28.6 million, or 25%, and $58.0 million, or 26%, for the three and six months ended June 30, 2024, respectively, compared to the same period in 2023[123]. - The company has achieved an approximately 40% revenue compound annual growth rate since its transformation commenced in 2018[114]. Expenses - Cost of sales decreased by $9.4 million, or 18%, and $7.0 million, or 8%, for the three and six months ended June 30, 2024, respectively, compared to the same period in 2023[124]. - Research and development expenses increased by $4.5 million, or 31%, and $9.3 million, or 33%, for the three and six months ended June 30, 2024, respectively, compared to the same period in 2023[125]. - Sales, general and administrative expenses increased by $25.4 million, or 29%, and $47.9 million, or 27%, during the three and six months ended June 30, 2024, respectively, compared to the same period in 2023[126]. - Litigation-related expenses decreased by $4.8 million, or 70%, and $3.6 million, or 35%, for the three and six months ended June 30, 2024, respectively, compared to the same period in 2023[126]. - Amortization of acquired intangible assets increased by $1.1 million, or 17%, during the six months ended June 30, 2024, compared to the same period in 2023[127]. - Transaction-related expenses decreased by $1.9 million, or 100%, and $2.0 million, or 106%, during the three and six months ended June 30, 2024, respectively, compared to the same period in 2023[128]. - Restructuring expenses increased due to costs associated with the relocation of office facilities in Paris, France[128]. Interest and Other Income - Interest expense, net, increased by $1.9 million, or 49%, and $3.4 million, or 44%, for the three and six months ended June 30, 2024, respectively, compared to the same period in 2023, primarily due to an additional $50.0 million drawn on the Braidwell Term Loan and higher interest rates[129]. - Other income, net, decreased by $2.2 million, or 93%, and $2.8 million, or 91%, during the three and six months ended June 30, 2024, respectively, mainly due to an employee retention credit received in the prior year[130]. Tax and Cash Flow - The income tax provision showed a change to a benefit of $286,000 for the three months ended June 30, 2024, compared to a provision of $50,000 in the same period in 2023, reflecting a 472% increase[131]. - Cash and cash equivalents decreased from $221.0 million at December 31, 2023, to $99.8 million at June 30, 2024[135]. - Cash used in operating activities was $49.8 million for the six months ended June 30, 2024, primarily due to inventory purchases[136]. - Cash used in investing activities was $69.5 million for the six months ended June 30, 2024, mainly for the purchase of surgical instruments[137]. Debt and Commitments - As of June 30, 2024, the company had $150.0 million outstanding under the Braidwell Term Loan, maturing on January 6, 2028, with an interest rate of Term SOFR plus 5.75%[139]. - The company had $54.9 million outstanding under the Revolving Credit Facility, maturing on or before September 29, 2027, with an interest rate of Term SOFR plus 3.5%[139]. - The company has an inventory purchase commitment of $9.8 million remaining under an agreement with a third-party supplier through December 2026[141]. - The company anticipates future capital requirements will depend on revenue growth, development spending, and market expansion efforts[132]. Strategic Goals - The company aims to revolutionize spine surgery through clinical distinction and has a comprehensive product portfolio addressing various spine pathologies[114].

Exhibit 99.1 ATEC Reports Second Quarter 2024 Financial Results And Raises Full-Year Guidance Surgical revenue grew 27% and drove total revenue growth of 25% to $146 million Full-year revenue and profitability guidance increased CARLSBAD, Calif., July 31, 2024 – Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter ended June 30, 2024, and recent corporate highlights. Second Qua ...

Alphatec (ATEC) recently announced the commercial launch of its EOS Insight, a groundbreaking, end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence (AI).Following the successful completion of the first customer implementation, David G. Schwartz and Craig McMains carried out the EOS Insight-informed surgeries at OrthoIndy Hospital. By modernizing surgery and displacing antiquated clinical procedures, EOS Insight enhances patient outcomes. The system's developmen ...

Alphatec Holdings, Inc. (NASDAQ:ATEC) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Patrick Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Joshua Jennings - TD Cowen David Saxon - Needham Vik Chopra - Wells Fargo Sean Lee - H.C. Wainwright Young Li - Jefferies Operator Good afternoon everyone and welcome to the webcast of ATEC’s First Quarter Financial Results. We would like to remind everyone that participants on the call will make forward-looking sta ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-52024 ALPHATEC HOLDINGS, INC. (Exact name of regi ...

Exhibit 99.1 ATEC Reports First Quarter 2024 Financial Results And Raises Full-Year Guidance Total revenue grew 27% to $138 million, with 30% growth in surgical revenue Adjusted EBITDA margin expanded 450 basis points Full-year revenue and adjusted EBITDA guidance increased to $601 million and $23 million, respectively CARLSBAD, Calif., May 7, 2024 – Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financia ...

Financial Data and Key Metrics Changes - Total revenue for 2023 was $482 million, reflecting a 37% growth compared to 2022 [3][23] - Adjusted EBITDA expanded by 890 basis points year-over-year, with a loss of $9 million for the full year 2023, an improvement of $29 million compared to 2022 [32][27] - Fourth quarter total revenue was $138 million, a 30% increase year-over-year and a 17% increase compared to the prior quarter [22][23] - Non-GAAP gross margin for the fourth quarter was 70%, up 310 basis points year-over-year [28] Business Line Data and Key Metrics Changes - Surgical revenue for 2023 was $423 million, a 40% increase compared to the previous year, with procedural volume growing by 31% [23][24] - Fourth quarter surgical revenue was $123 million, a 34% increase year-over-year, with procedural volume growth of 29% [22][23] - EOS revenue for 2023 was $59 million, a 24% increase compared to 2022, with fourth quarter EOS revenue at $15 million, up 5% year-over-year [24][22] Market Data and Key Metrics Changes - The company has increased its market share from approximately 1% to over 5% in the spine market, with some regions achieving up to 25% market share [4][12] - The market is characterized as 35% disrupted and 60% apathetic, presenting opportunities for growth [12] Company Strategy and Development Direction - The company aims to create clinical distinction to drive surgeon adoption and expand its product portfolio, with a commitment to launch 8 to 10 products per year [5][8] - Focus on expanding the lateral franchise, which addresses a $3 billion market opportunity, and integrating advanced technologies like SafeOp and robotic systems [7][14] - Plans to enhance the cervical portfolio and introduce 3D printed implants, along with the integration of navigated robotic elements [62][63] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the current market dynamics and the company's growth trajectory, emphasizing the importance of long-term strategies [12][39] - The company expects continued revenue growth of 23% in 2024, with surgical revenue projected to grow by approximately 25% [34][35] - Confidence in achieving cash flow breakeven by 2025, supported by a well-funded balance sheet and ongoing investments in revenue-generating assets [33][38] Other Important Information - The company raised $150 million in capital to support growth initiatives [4] - Adjusted EBITDA guidance for 2024 is approximately $22 million, including an $18 million provision for excess and obsolete inventory [35][36] Q&A Session Summary Question: Update on rep hiring cadence and market disruption - Management indicated that 94% of the market remains disruptive, and the hiring process is methodical, focusing on areas of greatest need [44] Question: Guidance on revenue cadence throughout the year - Revenue is considered a lag indicator, with expectations for a typical seasonal pattern in revenue growth throughout the year [49] Question: Insights on training and demand for ATEC products - There is a mix of new and returning surgeons, with significant interest in lateral surgeries and expanded applications [52][53] Question: Expectations for international contributions to revenue - International markets like Australia and New Zealand are starting to contribute, with Japan expected to show early revenue reflections [68][70] Question: Launch metrics for the updated EOS platform - Everything is on track for the EOS platform rollout in Q2 2024, with enthusiasm for the technology and its integration into workflows [71][73] Question: Achieving market share in key markets - The company highlighted that achieving higher market share often depends on establishing a strong lateral business and building relationships with surgeons [76]

Alphatec (ATEC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -32.14%. A quarter ago, it was expected that this medical equipment and supplies holding company would post a loss of $0.30 per share when it actually produced a loss of $0.35, delivering a surprise of -16.67%.Over the last four ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, today announced financial results for the quarter and full year ended December 31, 2023, and business highlights. Fourth Quarter and Full Year 2023 Financial Results Quarter EndedDecember 31, 2023 Year EndedDecember 31, 2023 Total revenues $ 138   $ 482   GAAP gross margin   69.0 %   64.3 % Non- ...